Lukens AK, Heidebrecht RW, Mulrooney C, et al. Diversity-oriented synthesis probe targets Plasmodium falciparum cytochrome b ubiquinone reduction site and synergizes with oxidation site inhibitors. J Infect Dis. 2015;211(7):1097-103. doi:10.1093/infdis/jiu565.

Bowers AA, Greshock TJ, West N, et al. Synthesis and conformation-activity relationships of the peptide isosteres of FK228 and largazole. J Am Chem Soc. 2009;131(8):2900-5. doi:10.1021/ja807772w.

Dandapani S, Lowe JT, Comer E, Marcaurelle LA. Diversity-oriented synthesis of 13- to 18-membered macrolactams via ring-closing metathesis. J Org Chem. 2011;76(19):8042-8. doi:10.1021/jo2011957.

Yoda S, Lin JJ, Lawrence MS, et al. Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound Mutations in ALK-Positive Lung Cancer. Cancer Discov. 2018;8(6):714-729. doi:10.1158/2159-8290.CD-17-1256.

Hieronymus H, Lamb J, Ross KN, et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell. 2006;10(4):321-30. doi:10.1016/j.ccr.2006.09.005.

Wagner BK, Haggarty SJ, Clemons PA. Chemical genomics: probing protein function using small molecules. Am J Pharmacogenomics. 2004;4(5):313-20. http://content.wkhealth.com/linkback/openurl?issn=1175-2203&volume=4&issue=5&spage=313.

Fitzgerald ME, Mulrooney CA, Duvall JR, et al. Build/couple/pair strategy for the synthesis of stereochemically diverse macrolactams via head-to-tail cyclization. ACS Comb Sci. 2012;14(2):89-96. doi:10.1021/co200161z.

Shaw AT, Friboulet L, Leshchiner I, et al. Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F. N Engl J Med. 2016;374(1):54-61. doi:10.1056/NEJMoa1508887.

Comer E, Beaudoin JA, Kato N, et al. Diversity-oriented synthesis-facilitated medicinal chemistry: toward the development of novel antimalarial agents. J Med Chem. 2014;57(20):8496-502. doi:10.1021/jm500994n.